Navigation Links
AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
Date:5/4/2012

SEATTLE, May 4, 2012 /PRNewswire/ -- AquaLiv Technologies, Inc. (OTCBB: AQLV) and its subsidiary, AquaLiv, Inc., have released an update concerning the previously announced $50 million capital infusion for AquaLiv, Inc. The company is also pleased to announce that it has executed a separate $3.5 million financing agreement.

In January, the company announced that its subsidiary, AquaLiv, Inc., expected the first tranche of funds from a $50 million funding round to arrive in April. Today the company released an update about the investment.

"The funder estimated that the first tranche of funds should be issued in April, but it is going to take longer," stated AquaLiv CEO, Craig Hoffman. "The Conditional Commitment Letter issued by the funder does not expire until June 15, so apparently they did anticipate this could take additional time to put together."

According to the company, the funding deal is progressing even though definitive contracts have not yet been issued. The funder requested an additional large package of underwriting documents on April 2nd and AquaLiv delivered the requested documents on April 13th. At this time, no further documentation has been requested.

"We hope to have more updates on this funding soon," added Mr. Hoffman. "However, in light of the economic environment and the difficulty in raising capital, we have continued with additional fundraising efforts during this period. This is not an indication of our confidence in the funding group, but a prudent business hedge for our future."

As part of that effort, the company recognized the need for its own funding separate from AquaLiv, Inc. In order to strengthen its operations and capital structure, the company executed a $3.5 million financing agreement. The company views the terms on the funding as significantly better than the cost of funds to the company previously.

The first funds to arrive, whether from the $50 million group or from another party, will be used to acquire Dr. Takemi Ichimura's (AquaLiv's Chief Science Officer) Japanese operations. The acquisition includes an established corporate entity with inventory and existing sales. The entity will be renamed AquaLiv Japan Co, Ltd. and its scope will encompass scientific research in addition to increased sales efforts throughout Asia.

"It is important that we both reduce our cost of funds and increase the share price to a point where institutional investors can consider AquaLiv," stated Bill Wright, CEO of AquaLiv Technologies, Inc. "The combination of strengthening our balance sheet, execution of funding, and sales increases through organic growth and the acquisition of Dr. Ichimura's operations should position us to attract larger shareholders interested in long term growth and results."

The company released its first agricultural product, AgSmart™ Rice, earlier this year, and is close to releasing their potato solution. AgSmart™ products increase crop yields without chemicals or genetic engineering and are organic standards compliant.

For more information about AquaLiv, visit their website: http://www.aqualiv.com

For more information about AquaLiv Technologies, Inc., visit their website: http://www.aqualivtech.com

About AquaLiv Technologies, Inc.:

AquaLiv Technologies, Inc., through its subsidiary, AquaLiv, Inc., offers unique solutions and for a variety of industries.

AquaLiv, Inc. is a life sciences research and development company creating novel products for numerous industries. The company's patented technology influences biological processes naturally and without chemical interaction. From increased crop yields to drug-free medicine, AquaLiv is providing innovative physics-based solutions to the world's largest problems. To learn more about AquaLiv, please visit: www.aqualiv.com.

Safe Harbor: Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact:
AquaLiv Technologies, Inc.
360-536-4220


'/>"/>
SOURCE AquaLiv Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Infrared Systems Internationals Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS
2. Infrared Systems Internationals Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Laymans Terms
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
6. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
7. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
8. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
9. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
10. AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing
11. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
Breaking Biology Technology:
(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):